Nurix Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Nurix Therapeutics
NRIX Stock  USD 15.79  0.31  2.00%   
Nurix Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Nurix Therapeutics' valuation are provided below:
Gross Profit
-232.9 M
Market Capitalization
1.6 B
Enterprise Value Revenue
12.7193
Revenue
84 M
Earnings Share
(3.05)
We have found one hundred twenty available fundamental ratios for Nurix Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Nurix Therapeutics last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 683.9 M in 2026. Enterprise Value is likely to drop to about 624.2 M in 2026

Nurix Therapeutics Total Revenue

50.91 Million

Check Nurix Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nurix Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 917.7 K, Net Interest Income of 26.5 M or Interest Income of 26.5 M, as well as many indicators such as Price To Sales Ratio of 24.15, Dividend Yield of 0.0 or PTB Ratio of 2.57. Nurix financial statements analysis is a perfect complement when working with Nurix Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Nurix Stock
Check out the analysis of Nurix Therapeutics Correlation against competitors.
For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.

Nurix Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets425.2 M791.4 M272.2 M
Slightly volatile
Other Current Liabilities66.2 M63.1 M18.9 M
Slightly volatile
Total Current Liabilities68.7 M99.4 M52.8 M
Slightly volatile
Other Liabilities42.9 M41.4 M23.3 M
Slightly volatile
Property Plant And Equipment Net88.2 M84 M25.9 M
Slightly volatile
Current Deferred Revenue34.9 M20.2 M29.9 M
Pretty Stable
Accounts Payable6.5 M12.9 M4.4 M
Slightly volatile
Cash298.2 M284 M88.1 M
Slightly volatile
Non Current Assets Total77.4 M93.5 M45.1 M
Slightly volatile
Non Currrent Assets Other10 M9.6 M2.7 M
Slightly volatile
Other Assets5.4 M5.7 M7.5 M
Pretty Stable
Cash And Short Term Investments716 M681.9 M242.6 M
Slightly volatile
Common Stock Total Equity30.4 K54 K22.6 K
Slightly volatile
Common Stock Shares Outstanding50.9 M99.7 M37.3 M
Slightly volatile
Short Term Investments236.1 M397.9 M143.8 M
Slightly volatile
Liabilities And Stockholders Equity425.2 M791.4 M272.2 M
Slightly volatile
Non Current Liabilities Total48.5 M56.6 M55 M
Pretty Stable
Capital Surpluse856.4 M815.6 M322.6 M
Slightly volatile
Other Current Assets16.8 M16 M5.9 M
Slightly volatile
Total Liabilities122.1 M171.8 M83.5 M
Slightly volatile
Property Plant And Equipment Gross133.8 M127.4 M36.9 M
Slightly volatile
Total Current Assets732.7 M697.8 M249.7 M
Slightly volatile
Capital Stock123.2 K117.3 K36.9 K
Slightly volatile
Non Current Liabilities Other25.2 M48.8 M19.1 M
Slightly volatile
Net Working Capital628.3 M598.4 M194.8 M
Slightly volatile
Short Term Debt5.9 M3.2 M4.2 M
Slightly volatile
Common Stock123.2 K117.3 K36.9 K
Slightly volatile
Property Plant Equipment12.6 M19.7 M10.1 M
Slightly volatile
Net Receivables1.3 M1.4 M7.5 M
Slightly volatile
Short and Long Term Debt Total67.3 M64.1 M23.6 M
Slightly volatile
Deferred Long Term Liabilities400 K450 K491.2 K
Slightly volatile

Nurix Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income26.5 M25.3 M6.9 M
Slightly volatile
Interest Income26.5 M25.3 M6.9 M
Slightly volatile
Depreciation And Amortization22.8 M21.7 M7.2 M
Slightly volatile
Interest Expense17.3 M16.5 M6.4 M
Slightly volatile
Selling General Administrative33.3 M60.7 M22.5 M
Slightly volatile
Total Revenue50.9 M96.6 M45.9 M
Slightly volatile
Other Operating Expenses446.3 M425.1 M154.4 M
Slightly volatile
Research Development372.1 M354.4 M128.4 M
Slightly volatile
Cost Of Revenue20.6 M21.7 M54.4 M
Pretty Stable
Total Operating Expenses423.6 M403.4 M104.8 M
Slightly volatile
Reconciled Depreciation22.8 M21.7 M8.2 M
Slightly volatile
Total Other Income Expense Net26.5 M25.3 M6.9 M
Slightly volatile
Non Operating Income Net Other2 M4 M1.9 M
Slightly volatile
Selling And Marketing Expenses4.9 M5.5 M6 M
Slightly volatile

Nurix Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation45.8 M43.7 M14.5 M
Slightly volatile
Begin Period Cash Flow70 M126.5 M48.5 M
Slightly volatile
Other Cashflows From Financing Activities7.8 M8.2 M15.3 M
Pretty Stable
Depreciation22.8 M21.7 M8.2 M
Slightly volatile
Capital Expenditures16.9 M16.1 M6 M
Slightly volatile
Total Cash From Financing Activities184 M274.4 M105.9 M
Slightly volatile
End Period Cash Flow299.4 M285.1 M88.6 M
Slightly volatile
Change To Netincome34.2 M32.6 M12 M
Slightly volatile
Change To Inventory7.2 M6.1 M9.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio24.1520.0716.2964
Slightly volatile
Days Sales Outstanding10.9711.54145
Slightly volatile
Stock Based Compensation To Revenue0.30.410.2253
Slightly volatile
Capex To Depreciation1.00.850.7586
Slightly volatile
EV To Sales21.9117.4514.7754
Slightly volatile
Payables Turnover1.841.9323.8708
Slightly volatile
Sales General And Administrative To Revenue0.540.570.4576
Slightly volatile
Research And Ddevelopement To Revenue2.513.32.266
Slightly volatile
Capex To Revenue0.130.150.1107
Slightly volatile
Cash Per Share5.586.164.9715
Slightly volatile
Days Payables Outstanding20519547.3477
Slightly volatile
Net Debt To EBITDA1.330.92.2601
Slightly volatile
Current Ratio3.656.323.2409
Slightly volatile
Receivables Turnover27.8632.7316.7749
Slightly volatile
Debt To Equity0.0620.09310.0543
Slightly volatile
Capex Per Share0.130.150.132
Slightly volatile
Revenue Per Share1.231.111.6215
Slightly volatile
Interest Debt Per Share0.350.580.3616
Slightly volatile
Debt To Assets0.04250.07290.0385
Slightly volatile
Operating Cycle10.9711.54144
Slightly volatile
Days Of Payables Outstanding20519547.3477
Slightly volatile
Ebt Per Ebit1.051.060.9481
Slightly volatile
Total Debt To Capitalization0.05630.08440.0505
Slightly volatile
Debt Equity Ratio0.0620.09310.0543
Slightly volatile
Quick Ratio3.656.323.2418
Slightly volatile
Net Income Per E B T0.770.90.9895
Slightly volatile
Cash Ratio2.72.571.359
Slightly volatile
Days Of Sales Outstanding10.9711.54145
Slightly volatile
Fixed Asset Turnover1.261.325.1451
Slightly volatile
Debt Ratio0.04250.07290.0385
Slightly volatile
Price Sales Ratio24.1520.0716.2964
Slightly volatile
Asset Turnover0.130.140.4821
Slightly volatile

Nurix Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap683.9 M1.3 B646.2 M
Slightly volatile
Enterprise Value624.2 M1.1 B586.9 M
Slightly volatile

Nurix Fundamental Market Drivers

Nurix Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
11th of April 2024
Next Financial Report
View
30th of November 2023
Next Fiscal Quarter End
View
8th of February 2024
Next Fiscal Year End
View
31st of August 2023
Last Quarter Report
View
30th of November 2022
Last Financial Announcement
View

About Nurix Therapeutics Financial Statements

Nurix Therapeutics investors use historical fundamental indicators, such as Nurix Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Nurix Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue20.2 M34.9 M
Total Revenue96.6 M50.9 M
Cost Of Revenue21.7 M20.6 M
Stock Based Compensation To Revenue 0.41  0.30 
Sales General And Administrative To Revenue 0.57  0.54 
Research And Ddevelopement To Revenue 3.30  2.51 
Capex To Revenue 0.15  0.13 
Revenue Per Share 1.11  1.23 
Ebit Per Revenue(3.91)(4.11)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill

Additional Tools for Nurix Stock Analysis

When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY